外泌体在前列腺癌诊疗中的研究进展

doi:10.16352/j.issn.1001-6325.2022.01.026

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (1): 163-167.doi: 10.16352/j.issn.1001-6325.2022.01.026

外泌体在前列腺癌诊疗中的研究进展

李英杰, 杨庭楷, 纪志刚^*, 文进^*

中国医学科学院北京协和医学院北京协和医院泌尿外科, 北京 100730

收稿日期:2021-09-07 修回日期:2021-11-05 出版日期:2022-01-05 发布日期:2022-01-05
通讯作者: ^* wjpumch@163.com; jzgjxmc@163.com
基金资助:
中国医学科学院中央级公益性科研院所基本科研业务费临床与转化医学研究基金(2019XK320027); 外国文教专家项目管理基金(G20190001645)

Progress of exosomes in diagnosis and treatment of prostate cancer

LI Ying-jie, YANG Ting-kai, JI Zhi-gang^*, WEN Jin^*

Department of Urology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2021-09-07 Revised:2021-11-05 Online:2022-01-05 Published:2022-01-05
Contact: ^* wjpumch@163.com; jzgjxmc@163.com

摘要/Abstract

摘要： 前列腺癌(PCa)是男性常见的恶性肿瘤。外泌体是存在于人体多种体液中的双层膜囊泡,携带核酸、蛋白等物质,介导细胞间通讯。外泌体可以促进前列腺癌的生长,协助免疫逃逸及化学治疗耐药,诱导血管生成、上皮细胞间充质转化(EMT)并为转移前生态位的形成提供条件,进而促进前列腺癌的侵袭和转移。基于肿瘤细胞与正常细胞分泌的外泌体成分不同,外泌体可作为前列腺癌诊断、预测侵袭转移、评估患者预后及药物疗效的生物标志物,并有望作为药物运输载体,在肿瘤的精准治疗中具有广阔的前景。

关键词: 前列腺癌, 外泌体, 生物标志物, 肿瘤

Abstract: Prostate cancer(PCa) is a common malignancy in males. Exosomes are lipid bilayer vesicles containing protein, mRNA and miRNA, which are active in intercellular communications. Exosomes promotes the development of prostate cancer, support immune evading and chemotherapy resistance, stimulate angiogenesis, induce epithelial-mesenchymal transition(EMT) of tumor cells, and contribute to the formation of pre-metastasis niche, thus promoting the invasion and metastasis of prostate cancer. Based on the role in tumor biological behavior and heterogeneity in different cells, exosomes hold great potentials as biomarker for diagnosis and prognosis of prostate cancer, and are expected to become a favorable drug carrier. It has a promising prospect for cancer therapy.

Key words: prostate cancer, exosomes, biomarkers, tumor

中图分类号:

R737.25

李英杰, 杨庭楷, 纪志刚, 文进. 外泌体在前列腺癌诊疗中的研究进展[J]. 基础医学与临床, 2022, 42(1): 163-167.

LI Ying-jie, YANG Ting-kai, JI Zhi-gang, WEN Jin. Progress of exosomes in diagnosis and treatment of prostate cancer[J]. Basic & Clinical Medicine, 2022, 42(1): 163-167.

参考文献

[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424.
[2]Saini S. PSA and beyond: alternative prostate cancer biomarkers[J]. Cell Oncol (Dordr), 2016, 39: 97-106.
[3]Cocozza F, Grisard E, Martin-Jaular L, et al. Snapshot: extracellular vesicles[J]. Cell, 2020, 182: 262-262.e1. doi: 10.1016/j.cell.2020.04.054.
[4]Albino D, Falcione M, Uboldi V, et al. Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer[J]. Commun Biol, 2021, 4: 119. doi:10.1038/s42003-020-01642-5.
[5]Dai Y, Gao X. Inhibition of cancer cell-derived exosomal microRNA-183 suppresses cell growth and metastasis in prostate cancer by upregulating TPM1[J]. Cancer Cell Int, 2021, 21: 145. doi:10.1186/s12935-020-01686-x.
[6]Herrera M, Llorens C, Rodríguez M, et al. Differential distribution and enrichment of non-coding RNAs in exosomes from normal and cancer-associated fibroblasts in colorectal cancer[J]. Mol Cancer, 2018, 17: 114. doi: 10.1186/s12943-018-0863-4.
[7]Wu M, Wang G, Hu W, et al. Emerging roles and therapeutic value of exosomes in cancer metastasis[J]. Mol Cancer, 2019, 18: 53. doi: 10.1186/s12943-019-0964-8.
[8]Mashouri L, Yousefi H, Aref AR, et al. Exosomes: composition, biogenesis, and mechanisms in cancer meta-stasis and drug resistance[J]. Mol Cancer, 2019, 18: 75. doi: 10.1186/s12943-019-0991-5.
[9]Lorenc T, Klimczyk K, Michalczewska I, et al. Exosomes in prostate cancer diagnosis, prognosis and therapy[J]. Int J Mol Sci, 2020, 21: 2118. doi:10.3390/ijms21062118.
[10]Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J]. Nature, 2018, 560: 382-386.
[11]Sinha D, Roy S, Saha P, et al. Trends in research on exosomes in cancer progression and anticancer therapy[J]. Cancers, 2021, 13: 326. doi:10.3390/cancers13020326.
[12]Li Y, Li Q, Li D, et al. Exosome carrying PSGR promotes stemness and epithelial-mesenchymal transition of low aggressive prostate cancer cells[J]. Life Sci, 2021, 264: 118638. doi:10.1016/j.lfs.2020.118638.
[13]Guo Y, Ji X, Liu J, et al. Effects of exosomes on pre-metastatic niche formation in tumors[J]. Mol Cancer, 2019, 18: 39. doi:10.1186/s12943-019-0995-1.
[14]Akoto T, Saini S. Role of exosomes in prostate cancer metastasis[J]. Int J Mol Sci, 2021, 22: 3528. doi:10.3390/ijms22073528.
[15]Yu L, Sui B, Fan W, et al. Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p[J]. J Extracell Vesicles, 2021, 10: e12056. doi:10.1002/jev2.12056.
[16]Borel M, Lollo G, Magne D, et al. Prostate cancer-derived exosomes promote osteoblast differentiation and activity through phospholipase D2[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866: 165919. doi:10.1016/j.bbadis.2020.165919.
[17]Zhang Y, Chen B, Xu N, et al. Exosomes promote the transition of androgen-dependent prostate cancer cells into androgen-independent manner through up-regulating the heme oxygenase-1[J]. Int J Nanomedicine, 2021, 16: 315-327.
[18]Zhang Y, Zhao J, Ding M, et al. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis[J]. J Exp Clin Cancer Res, 2020, 39: 282. doi:10.1186/s13046-020-01761-1.
[19]Shan G, Gu J, Zhou D, et al. Cancer-associated fibroblast-secreted exosomal miR-423-5p promotes chemotherapy resistance in prostate cancer by targeting GREM2 through the TGF-β signaling pathway[J]. Exp Mol Med, 2020, 52: 1809-1822.
[20]Duca RB, Massillo C, Dalton GN, et al. miR-19b-3p and miR-101-3p as potential biomarkers for prostate cancer diagnosis and prognosis[J]. Am J Cancer Res, 2021, 11: 2802-2820.
[21]Ji J, Chen R, Zhao L, et al. Circulating exosomal mRNA profiling identifies novel signatures for the detection of prostate cancer[J]. Mol Cancer, 2021, 20: 58. doi:10.1186/s12943-021-01349-z.
[22]Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer[J]. Eur Urol, 2015, 67: 33-41.
[23]Guo T, Wang Y, Jia J, et al. The identification of plasma exosomal miR-423-3p as a potential predictive biomarker for prostate cancer castration-resistance development by plasma exosomal miRNA sequencing[J]. Front Cell Dev Biol, 2020, 8: 602493. doi:10.3389/fcell.2020.602493.
[24]Shin S, Park YH, Jung SH, et al. Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer[J]. NPJ Genom Med, 2021, 6: 45. doi:10.1038/s41525-021-00212-w.
[25]Krishn SR, Singh A, Bowler N, et al. Prostate cancer sheds the αvβ3 integrin in vivo through exosomes[J]. Matrix Biol, 2019, 77: 41-57.
[26]Del Re M, Conteduca V, Crucitta S, et al. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide[J]. Prostate Cancer Prostatic Dis, 2021, 24: 524-531.
[27]Severic M, Ma G, Pereira SGT, et al. Genetically-engineered anti-PSMA exosome mimetics targeting advanced prostate cancer in vitro and in vivo[J]. J Control Release, 2021, 330: 101-110.
[28]Gaballa R, Ali HEA, Mahmoud MO, et al. Exosomes-mediated transfer of Itga2 promotes migration and invasion of prostate cancer cells by inducing epithelial-mesenchy-mal transition[J]. Cancers (Basel), 2020, 12: 2300. doi:10.3390/cancers12082300.
[29]Han Q, Xie QR, Li F, et al. Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer[J]. Theranostics, 2021, 11: 6526-6541.
[30]Xu Z, Zeng S, Gong Z, et al. Exosome-based immunotherapy: a promising approach for cancer treatment[J]. Mol Cancer, 2020, 19: 160. doi:10.1186/s12943-020-01278-3.
[31]Morishita M, Takahashi Y, Matsumoto A, et al. Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA[J]. Biomaterials, 2016, 111: 55-65.
[32]Kim J, Shim JS, Han BH, et al. Hydrogel-based hybridization chain reaction (HCR) for detection of urinary exosomal miRNAs as a diagnostic tool of prostate cancer[J]. Biosens Bioelectron, 2021, 192: 113504. doi:10.1016/j.bios.2021.113504.

外泌体在前列腺癌诊疗中的研究进展

Progress of exosomes in diagnosis and treatment of prostate cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	谢思安, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 刘思. VAV1是动脉粥样硬化预后的潜在靶点和生物标志物[J]. 基础医学与临床, 2022, 42(7): 1092-1098.
[2]	李昱阳, 李钊璇, 罗云萍, 陈翀. 小鼠乳腺癌干细胞免疫相关分子表达和免疫浸润的分析[J]. 基础医学与临床, 2022, 42(6): 876-882.
[3]	周岚, 张生贵, 胡祖梁, 王添贤, 岳鹏鹏, 于鸿浩. 基于CRISPR/Cas9系统高效编辑小鼠miR let-7a[J]. 基础医学与临床, 2022, 42(6): 857-863.
[4]	马瑞, 杨黎星, 陈秋霞, 仇佳星, 王钰铖, 鞠瑞, 郭磊. 羧胺三唑乳清酸盐对小鼠胶质瘤相关巨噬细胞系促癌表型的影响[J]. 基础医学与临床, 2022, 42(5): 701-707.
[5]	李钊璇, 罗云萍, 陈翀. 气液交互法培养小鼠来源的肿瘤类器官的建立及优化[J]. 基础医学与临床, 2022, 42(5): 782-787.
[6]	周智恩, 严维刚, 周毅, 左宇志, 梁震. 拼图(Jigasaw)教学法应用于前列腺靶向穿刺教学中的效果评估[J]. 基础医学与临床, 2022, 42(5): 844-847.
[7]	白小腾, 孙晓红, 赵翔宇, 李子坚. 检测循环细胞游离DNA用于淋巴瘤诊断和评估的研究进展[J]. 基础医学与临床, 2022, 42(4): 661-666.
[8]	何丹, 阮中宝. 细胞外囊泡在心房颤动发病中的作用[J]. 基础医学与临床, 2022, 42(4): 671-674.
[9]	宋昊昕, 叶菜英, 朱蕾. Blau综合征细胞模型的建立[J]. 基础医学与临床, 2022, 42(3): 406-410.
[10]	刘畅, 郭向阳. 局部麻醉药物在肿瘤转移和复发中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 512-515.
[11]	谢丽君, 朱高红, 赵继华, 张海波, 王娇. 甲状腺癌肿瘤干细胞的来源和存活途径[J]. 基础医学与临床, 2022, 42(2): 321-324.
[12]	曾笛, 张聪敏, 郭金培, 张楠, 马二民. miR-125靶向SMAD4抑制脂多糖诱导的人结肠上皮细胞向肿瘤细胞转化[J]. 基础医学与临床, 2022, 42(2): 249-254.
[13]	尹婕, 潘凌亚, 温仪萍, 黄虹, 曾靖, 李晓莹, 韩甜甜, 金滢, 李艳. 人上皮性卵巢癌细胞系侧群细胞的肿瘤干细胞样细胞生物学特性及膜蛋白差异表达的鉴定[J]. 基础医学与临床, 2022, 42(2): 221-227.
[14]	冯天瑞, 严维刚. 环状RNAs在前列腺癌中的研究进展[J]. 基础医学与临床, 2022, 42(1): 179-183.
[15]	谢聪聪, 王雪莹, 安卓, 姚胜杰, 马婧, 王树松. 胚胎发育生物标志物的研究进展[J]. 基础医学与临床, 2022, 42(1): 168-172.